Schwartz M
Department of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel.
Surv Ophthalmol. 2001 May;45 Suppl 3:S256-60; discussion S273-6. doi: 10.1016/s0039-6257(01)00208-9.
In glaucoma, as in other degenerative diseases of the central nervous system (CNS), there are some neurons which, although susceptible to degeneration, are amenable to neuroprotection. Until very recently, attempts to attenuate the spread of damage after CNS trauma or in neurodegenerative diseases did not include recruitment of the immune system, because it was assumed that in the CNS any immune activity, particularly autoimmune activity, would be harmful. Using the injured optic nerve of the rat as a model, we recently showed, however, that this 'secondary degeneration' can be slowed down by a well-controlled adaptive immune response, which is mediated by T cells against CNS self-antigens, such as myelin basic protein (MBP), and can be achieved either by passive transfer of MBP-activated T cells or by active immunization with MBP. Accordingly, we suggested that autoimmune T cells can be neuroprotective. We further showed that the neuroprotective autoimmunity is a physiological response to the injury, perhaps insufficient in its natural state, but amenable to boosting. The neuroprotective activity of these T cells probably depends on their reactivation by their specific antigen after they are targeted to the injured nerve. As nerve degeneration is initiated and sustained by many factors, it would probably best be counteracted by a comprehensive type of therapy rather than treatment that addresses only some aspects of nerve damage. T cell therapy, being physiological rather than pharmaceutical in nature, may provide a global answer. However, since the neuroprotective immune response is directed against the self, it must be rigorously regulated to avoid inducing an autoimmune disease. We showed that the synthetic copolymer Cop-1 can passively or actively evoke T cell-mediated neuroprotection, probably by cross-reacting with MBP. Safe synthetic peptides that resemble self-antigens and are cross-activated by CNS-associated self antigens may be a useful starting point for the development of anti-self immunity for neuroprotective purposes.
在青光眼以及其他中枢神经系统(CNS)退行性疾病中,存在一些神经元,它们虽易发生退变,但可进行神经保护。直到最近,在中枢神经系统创伤后或神经退行性疾病中,试图减轻损伤扩散的尝试都未涉及免疫系统的募集,因为人们认为在中枢神经系统中,任何免疫活动,尤其是自身免疫活动,都是有害的。然而,我们最近以大鼠受损视神经为模型表明,这种“继发性退变”可通过由T细胞介导的针对中枢神经系统自身抗原(如髓磷脂碱性蛋白(MBP))的良好控制的适应性免疫反应来减缓,这可通过被动转移MBP激活的T细胞或用MBP进行主动免疫来实现。因此,我们认为自身免疫性T细胞具有神经保护作用。我们还进一步表明,神经保护性自身免疫是对损伤的一种生理反应,其在自然状态下可能不足,但可增强。这些T细胞的神经保护活性可能取决于它们在靶向损伤神经后被其特异性抗原重新激活。由于神经退变由多种因素引发并持续,可能最好通过一种综合治疗方式来对抗,而不是仅针对神经损伤某些方面的治疗。T细胞疗法本质上是生理性的而非药物性的,可能提供一个全面的解决方案。然而,由于神经保护性免疫反应是针对自身的,必须严格调控以避免诱发自身免疫性疾病。我们表明合成共聚物Cop - 1可被动或主动引发T细胞介导的神经保护,可能是通过与MBP交叉反应实现的。类似于自身抗原且被中枢神经系统相关自身抗原交叉激活的安全合成肽可能是开发用于神经保护目的的抗自身免疫的有用起点。